Latest Close
₹3,074.50
+3.86%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹2,838.95
200 DMA
₹2,167.61
1 year gain / loss
+₹1,168.70(+61.32%)
₹1,905.80 → ₹3,074.50· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Market Cap
₹51,112.11 Cr
P/E
45.28×
Sector -38.72× · above
P/B
4.93×
Sector 4.11× · above
EV / EBITDA
23.46×
Sector 19.14× · above
ROE
9.92%
Sector 0.37%
ROCE
14.02%
Sector 6.55%
ROA
9.02%
Sector -17.04%
Cash Flow / Profit
1.00×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 1,861.5 +0.4% | 434.98 | 316.96 -13.6% |
| Mar 2026 | 1,854.26 +5.4% | 505.8 | 366.68 +40.2% |
| Dec 2025 | 1,758.53 +11.9% | 362.13 | 261.48 +42.4% |
| Sep 2025 | 1,571.04 | 283.92 | 183.68 |
Dividend
11 Aug 2026 · ₹20